
Annual report 2025
added 04-15-2026
GeoVax Labs Long-Term Debt 2011-2026 | GOVX
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt GeoVax Labs
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 580 K | - | - | - | - | 14.7 K | 27.2 K | 39.6 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 580 K | 14.7 K | 165 K |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
273 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
68.2 M | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
4 M | - | - | $ 1.01 B | ||
|
Midatech Pharma plc
MTP
|
4.76 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.42 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
130 K | $ 0.9 | -2.33 % | $ 6.62 M | ||
|
Biophytis SA
BPTS
|
1.83 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
173 M | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
42 M | $ 21.96 | -0.68 % | $ 3.64 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
278 K | - | -1.52 % | $ 24.7 M | ||
|
Advaxis
ADXS
|
8.14 M | - | -9.65 % | $ 45.9 M | ||
|
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
28.3 M | - | 0.23 % | $ 488 M | ||
|
Aligos Therapeutics
ALGS
|
122 K | $ 6.4 | 4.4 % | $ 63.3 M | ||
|
Allakos
ALLK
|
38.2 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
1.13 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - | ||
|
Amphastar Pharmaceuticals
AMPH
|
620 M | $ 21.41 | 1.9 % | $ 1 B | ||
|
Applied Molecular Transport
AMTI
|
49 K | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
31 K | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
171 K | - | -2.5 % | $ 5.88 M | ||
|
Applied Therapeutics
APLT
|
38 K | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
22.1 M | - | -39.0 % | $ 4.57 M | ||
|
AgeX Therapeutics
AGE
|
2.95 M | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
1.88 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
1.29 M | - | 17.91 % | $ 11.1 M | ||
|
BioNTech SE
BNTX
|
231 M | $ 105.46 | -0.09 % | $ 27.2 B | ||
|
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
9.12 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
45 M | $ 4.08 | 0.25 % | $ 436 M | ||
|
Arcutis Biotherapeutics
ARQT
|
108 M | $ 23.26 | 1.75 % | $ 2.96 B | ||
|
Ayala Pharmaceuticals
AYLA
|
1.33 M | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
66.8 M | $ 1.44 | -5.88 % | $ 383 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
AstraZeneca PLC
AZN
|
17.5 B | - | - | $ 96.9 B | ||
|
AVROBIO
AVRO
|
188 K | - | 1083.1 % | $ 745 M | ||
|
BioDelivery Sciences International
BDSI
|
78.5 M | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
962 M | - | 0.49 % | $ 251 B | ||
|
Akero Therapeutics
AKRO
|
529 K | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
25.4 M | - | - | $ 867 M | ||
|
bluebird bio
BLUE
|
37.7 M | - | - | $ 546 M | ||
|
ContraFect Corporation
CFRX
|
2.21 M | - | -5.16 % | $ 5.39 M | ||
|
Fennec Pharmaceuticals
FENC
|
30.9 M | $ 6.84 | 2.7 % | $ 195 M | ||
|
BioXcel Therapeutics
BTAI
|
84.7 M | $ 1.06 | -3.64 % | $ 12.9 M | ||
|
Cabaletta Bio
CABA
|
2.88 M | $ 2.95 | -3.28 % | $ 296 M | ||
|
Cara Therapeutics
CARA
|
85 K | - | -3.03 % | $ 260 M | ||
|
Allena Pharmaceuticals
ALNA
|
210 K | - | 3.16 % | $ 1.9 M |